Gabrielle Wanneh

Maryland

Drug Pricing Reporter at Inside Health Policy

Mark 5:34 || Earthbender 🌿 || Drug pricing reporter @InHealthPolicy by day, vigorously watching cartoons and working on my wildest dreams by night.. 🪴🌻✨

Featured in: Favicon

insidehealthpolicy.com Favicon

msn.com

usnews.com Favicon

yahoo.com

politico.com Favicon

edweek.org Favicon

aarp.org

dcist.com

whsv.com

afro.com + 6 more

Articles

CBP Warns Drug Makers To Ensure Compliance With MFN EO In Trade Situations

1 week ago | insidehealthpolicy.com | Gabrielle Wanneh

Drug companies must declare prescription drug values matching President Donald Trump’s recent “most favored nation” executive order when submitting import or export documentation to the United States Customs and Border Protection (CBP) or face the fullest extent of violation enforcement measures possible, the agency warned this month.
Trump’s 340B Request Could Further Convolute Existing Program Issues

1 week ago | insidehealthpolicy.com | Gabrielle Wanneh

President Donald Trump’s demand for health centers to make insulin and injectable epinephrine available at low prices offered under the 340B drug discount program is unlikely to solve any of the existing operational issues within the program that stakeholders want resolved, health policy experts tell Inside Health Policy.
Alzheimer’s Advocates Wary Of RFK Jr.’s Rhetoric On Amyloid Drugs

1 week ago | insidehealthpolicy.com | Jessica Karins |Gabrielle Wanneh

HHS Secretary Robert F. Kennedy Jr.’s comments about fraudulent research in treating Alzheimer’s and alleged corruption at the National Institutes of Health (NIH) are raising the specter among advocates that there will be new restrictions on the controversial class of drugs that combat amyloid beta plague in the brain.
ICER Preps For Inaugural Annual Report On Drug List Prices & Access

2 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The Institute for Clinical and Economic Review on Friday (May 23) released a protocol detailing how it plans to gather information for a new report on prescription drug list prices and the barriers patients face when trying to access their medications.
Pharma 340B Rebate Model Stopped For Now As Court Defers To HRSA

2 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

Hospitals chalked up an initial win in their bid to stop drug makers from replacing upfront 340B drug discounts with back-end rebates when a federal DC district judge ruled last week the ultimate decision on the policy rests with the Health Resources and Services Administration -- but the win could be short-lived as HRSA has sent warning letters against four drug makers asking them to stop their rebate policies although the Trump administration has yet to issue a broad policy decision.
Draft Guidance For Third Negotiation Cycle Ushers In Part B Drugs & Renegotiation

3 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The latest draft guidance for Medicare drug price negotiations clarifies that a drug company's introduction of a fixed combination drug with an altered formulation and delivery method can no longer reset the timeline for when the original drug is eligible for negotiation, closing a loophole in previous guidance that sources say could have allowed Merck and Bristol Myers Squibb to seek protections for their subcutaneous versions of Part B cancer treatments Keytruda and Opdivo.
HHS Launches AI, Informatic Projects To Shore Up Domestic Drug Production

3 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The Trump administration on Thursday (May 15) launched four projects aimed at bolstering manufacturing for eight sterile injectable and oral medications, as well as their active ingredients, within the United States between now and next spring, using a mix of artificial intelligence, machine learning, and information science and technology to revolutionize how drugs are produced domestically.
Rejection Of AstraZeneca Lawsuit May Have Considerable Impact On Remaining Cases

3 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

The Third Circuit Court of Appeals’ rejection of AstraZeneca’s lawsuit this month alleging the Inflation Reduction Act’s Medicare drug price negotiation program violates the drug maker’s due process could set a precedent for several other cases that allege the implementation of price negotiations invokes a taking of a drug company’s private patented products, violating the Fifth amendment Takings clause.
E&C Reconciliation Bill Includes PBM, Orphan Drug, Pharmacy Transparency Reforms

3 weeks ago | insidehealthpolicy.com | Gabrielle Wanneh

House Energy & Commerce Republicans' budget reconciliation bill includes myriad pharmacy benefit manager reforms, an expansion of the orphan drug exclusion in Medicare drug price negotiations, and a requirement that pharmacies complete national acquisition cost surveys.
Hawley, Welch Introduce MFN Bill As WH Eyes Policy For Medicaid

1 month ago | insidehealthpolicy.com | Gabrielle Wanneh

As the White House tests the waters on whether to base Medicaid drug payments on lower prices overseas as a cost-saver for Republicans’ emerging reconciliation package, Sens. Josh Hawley (R-MO) and Peter Welch (D-VT) simultaneously are pushing legislation Monday (May 5) that would fine drug companies if they charge more for prescription drugs in the United States than they charge in other countries.